Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...

Teos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

Patients with severe asthma (4.6% of asthma patients) are more likely to be female, older, and have higher BMI than those with non-severe asthma.

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 ...

GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...